Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Stock Information for Oncolytics Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.